FENC vs. GLUE, SANA, PROK, MGTX, RGNX, ALLO, AURA, TSHA, SGMO, and PRME
Should you be buying Fennec Pharmaceuticals stock or one of its competitors? The main competitors of Fennec Pharmaceuticals include Monte Rosa Therapeutics (GLUE), Sana Biotechnology (SANA), ProKidney (PROK), MeiraGTx (MGTX), REGENXBIO (RGNX), Allogene Therapeutics (ALLO), Aura Biosciences (AURA), Taysha Gene Therapies (TSHA), Sangamo Therapeutics (SGMO), and Prime Medicine (PRME). These companies are all part of the "biological products, except diagnostic" industry.
Fennec Pharmaceuticals vs.
Fennec Pharmaceuticals (NASDAQ:FENC) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, community ranking, risk, valuation and institutional ownership.
Fennec Pharmaceuticals received 184 more outperform votes than Monte Rosa Therapeutics when rated by MarketBeat users. Likewise, 66.22% of users gave Fennec Pharmaceuticals an outperform vote while only 48.28% of users gave Monte Rosa Therapeutics an outperform vote.
55.5% of Fennec Pharmaceuticals shares are held by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are held by institutional investors. 11.0% of Fennec Pharmaceuticals shares are held by company insiders. Comparatively, 6.5% of Monte Rosa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Monte Rosa Therapeutics has a net margin of 0.00% compared to Fennec Pharmaceuticals' net margin of -2.30%. Fennec Pharmaceuticals' return on equity of -53.38% beat Monte Rosa Therapeutics' return on equity.
Fennec Pharmaceuticals has a beta of 0.27, meaning that its share price is 73% less volatile than the S&P 500. Comparatively, Monte Rosa Therapeutics has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500.
Fennec Pharmaceuticals has higher revenue and earnings than Monte Rosa Therapeutics. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Fennec Pharmaceuticals had 2 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 3 mentions for Fennec Pharmaceuticals and 1 mentions for Monte Rosa Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 0.99 beat Fennec Pharmaceuticals' score of 0.61 indicating that Monte Rosa Therapeutics is being referred to more favorably in the news media.
Fennec Pharmaceuticals currently has a consensus target price of $13.67, indicating a potential upside of 182.95%. Monte Rosa Therapeutics has a consensus target price of $16.00, indicating a potential upside of 87.79%. Given Fennec Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Fennec Pharmaceuticals is more favorable than Monte Rosa Therapeutics.
Summary
Fennec Pharmaceuticals beats Monte Rosa Therapeutics on 12 of the 17 factors compared between the two stocks.
Get Fennec Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for FENC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fennec Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:FENC) was last updated on 11/21/2024 by MarketBeat.com Staff
